Niki BioSolutions Inc, formerly Aptorum Group Ltd is a clinical-stage biopharmaceutical company... Show more
a developer of therapeutic and diagnostic products
Industry Biotechnology
A.I.dvisor indicates that over the last year, NIKI has been loosely correlated with HLSQ. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if NIKI jumps, then HLSQ could also see price increases.
| Ticker / NAME | Correlation To NIKI | 1D Price Change % | ||
|---|---|---|---|---|
| NIKI | 100% | -8.70% | ||
| HLSQ - NIKI | 60% Loosely correlated | N/A | ||
| CANF - NIKI | 48% Loosely correlated | -0.37% | ||
| APVO - NIKI | 46% Loosely correlated | +3.28% | ||
| ICU - NIKI | 45% Loosely correlated | -0.58% | ||
| MLEC - NIKI | 45% Loosely correlated | -2.69% | ||
More | ||||
NIKI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 40 of 44 cases where NIKI's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NIKI's RSI Indicator exited the oversold zone, 34 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 21 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for NIKI just turned positive on September 22, 2026. Looking at past instances where NIKI's MACD turned positive, the stock continued to rise in 33 of 43 cases over the following month. The odds of a continued upward trend are 77%.
The 50-day moving average for NIKI moved below the 200-day moving average on September 25, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NIKI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for NIKI entered a downward trend on September 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.178) is normal, around the industry mean (26.453). P/E Ratio (3.000) is within average values for comparable stocks, (42.231). Projected Growth (PEG Ratio) (0.120) is also within normal values, averaging (9.058). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. NIKI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NIKI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.